Less is more: Low-dose olanzapine curbs chemo-induced nausea without the sedation
Peer-Reviewed Publication
This month, we're turning our attention to Breast Cancer Awareness Month, a time dedicated to increasing awareness, supporting early detection, and highlighting the ongoing research shaping the future of breast cancer treatment and prevention.
Updates every hour. Last Updated: 12-Oct-2025 08:11 ET (12-Oct-2025 12:11 GMT/UTC)
Chemotherapy-induced nausea and vomiting can severely impact patients’ quality of life and treatment adherence. In a major clinical trial, researchers from Japan tested whether a low, 5 mg dose of olanzapine taken at home after chemotherapy could reduce these side effects without causing heavy sedation. The study found that this approach significantly improved outcomes compared to placebo, offering a safer, more affordable strategy that could reshape supportive cancer care, especially in outpatient and resource-limited settings.
In a major stride toward tackling aggressive breast cancer, researchers from The Hebrew University of Jerusalem have developed druglike molecules that degrade a previously “undruggable” cancer-driving protein. The target, HuR—an RNA-binding protein known for stabilizing oncogenic messages—has long eluded traditional therapies. Now, using next-generation strategies involving molecular glues and PROTACs, researchers have uncovered a promising route to disarm HuR and suppress tumor growth from the inside out.
A first-of-its-kind study, led by LaShae Rolle, a 27 y/o breast cancer researcher, survivor and elite powerlifter, challenges the long-held belief that cancer patients should stick to low- or moderate exercise and suggests that with individualized and symptom-informed exercise planning, even powerlifting can be safe and beneficial.